9
landing page
FasterCures and COVID-19
Ending the Crisis
The goal of FasterCures is to understand how industry and government are working
to end the COVID-19 crisis. To help us in this mission, we have created Four Pillars., FasterCures: COVID-19 Action Recommendations
Learn More About the Recommendations
+ Read More
panel
FasterCures Roundtable (Invite only)
As health systems worldwide recover and rebuild in the retention wake of COVID-19, the importanc
e of early preparation, multi-stakeholder collaboration, and constant innovation must not be forgotten.
+ Read More
article
FasterCures Statement of Support for 21st Century Cures 2.0 Legislation
FasterCures, a center of the Milken Institute, has long supported policies that accelerate new, cutt
ing-edge biomedical innovations to patients.
+ Read More
report
A Call to Action for Health Equity: Solutions from the Front Lines for Local and National Efforts
FasterCures is advancing system change within biomedical research to focus on and value diversity a
nd representation within clinical trials and the workforce.
+ Read More
report
The Promise of Multi-Cancer Early Detection Technologies in Encouraging Research and Development
New blood-based technologies, known as multi-cancer early detection (MCED) tests, are entering 
;the market and can identify multiple cancers early and simultaneously.
+ Read More
report
COVID-19 Silver Linings for Biomedical Innovation: Implementation Roadmap
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical i
nnovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not think possible.
+ Read More
report
Achieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research Ecosystem
Clinical trials have been used for decades as the primary way by which researchers determine if a n
ew treatment is safe and effective for human use.
+ Read More
video
Advances in Science: Beyond “One Disease at a Time:” Therapeutic Platforms for Monogenic Disease
Guest speaker Philip John (P.J.) Brooks, PhD, acting director of the Division of Rare Diseases Res
earch Innovation at the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) delivered a presentation about cell an
+ Read More
article
Letter of Support: Reauthorization of Food and Drug Administration (FDA) User Fee Programs
Submitted electronically